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ABSTRACT
Vascular endothelial growth factor A (VEGF-A) regulates many
aspects of vascular physiology such as cell migration, proliferation,
tubulogenesis and cell-cell interactions. Numerous isoforms of
VEGF-A exist but their physiological significance is unclear. Here
we evaluated two different VEGF-A isoforms and discovered
differential regulation of cytosolic calcium ion flux, transcription
factor localisation and endothelial cell response. Analysis of
VEGF-A isoform-specific stimulation of VEGFR2-dependent signal
transduction revealed differential capabilities for isoform activation
of multiple signal transduction pathways. VEGF-A165 treatment
promoted increased phospholipase Cc1 phosphorylation, which
was proportional to the subsequent rise in cytosolic calcium ions, in
comparison to cells treated with VEGF-A121. A major consequence
of this VEGF-A isoform-specific calcium ion flux in endothelial
cells is differential dephosphorylation and subsequent nuclear
translocation of the transcription factor NFATc2. Using reverse
genetics, we discovered that NFATc2 is functionally required for
VEGF-A-stimulated endothelial cell migration but not tubulogenesis.
This work presents a new mechanism for understanding how
VEGF-A isoforms program complex cellular outputs by converting
signal transduction pathways into transcription factor redistribution
to the nucleus, as well as defining a novel role for NFATc2 in
regulating the endothelial cell response.
KEY WORDS: VEGF-A, NFATc2, Calcium, Endothelial, Cell
migration
INTRODUCTION
There are 58 human receptor tyrosine kinases (RTKs) which are
sub-classified into 20 families. These Type I membrane proteins
regulate animal development, health and disease states (Lemmon
and Schlessinger, 2010). Upon ligand-binding, RTK monomers
undergo dimerisation followed by trans-autophosphorylation of
cytoplasmic tyrosine residues, enabling the recruitment and
phosphorylation of a vast array of signal transduction enzymes
and adaptor proteins. RTKs are key targets for new therapeutics
but successful drug design is complicated by the increasing
number of ligands discovered to bind to each RTK. The
physiological relevance for the expression of numerous ligands
is unclear; many studies have based their conclusions on studying
the effects of a single ligand for a specific RTK.
This complexity is exemplified by the human vascular
endothelial growth factor (VEGF) family, which comprises 5
family members [VEGF-A, VEGF-B, VEGF-C, VEGF-D and
placental growth factor (PlGF)]. Together this family of growth
factors regulate angiogenesis and lymphangiogenesis through
differentially binding to an array of Class V RTKs (VEGFR1-3)
and co-receptors such as neuropilins i.e. NRP1 and NRP2 (Koch
et al., 2011). The VEGFA gene is located on chromosome 6p21.3
(Vincenti et al., 1996); transcription of this gene leads to the
formation of a pre-mRNA transcript with a coding region that
contains 8 exons and 7 introns. Alternative splicing of the VEGFA
mRNA transcript gives rise to at least 7 pro-angiogenic isoforms,
which all bind to both VEGFR1 and VEGFR2 (Robinson and
Stringer, 2001). However, it is also believed that, the pre-mRNA
splicing machinery can also generate anti-angiogenic isoforms
via alternate splice site selection events (Harper and Bates, 2008).
These events termed proximal splice site selection (PSS) and
distal splice site selection (DSS), determine the terminal amino
acid sequence (exon 8) switching between the pro-angiogenic
sequence CDKPRR (exon 8a) or the anti-angiogenic sequence
SLTRKD (exon 8b) (Harper and Bates, 2008). This raises the
question as to the functional relevance of the different VEGF-A
isoforms; most studies have focused solely on the VEGF-A165
isoform, which is secreted by both vascular and non-vascular
cells.
VEGF-A is a crucial regulator of angiogenesis, modulating
diverse endothelial responses such as cell proliferation, migration,
tubulogenesis, vascular permeability and leukocyte recruitment.
VEGFA gene dosage is critical for normal development as
heterozygous VEGFA (+/2) knockout mice embryos are not
viable and die between E11 and E12 due to a deformed vascular
network (Carmeliet et al., 1996; Ferrara et al., 1996). VEGFR1 and
VEGFR2 can both bind different VEGF-A isoforms but it is
unclear as to how the different RTK-ligand complexes regulate
endothelial and vascular function. Nonetheless, both VEGFR1 and
VEGFR2 encode gene products that are essential for correct
vascular development and animal function (Fong et al., 1995;
Shalaby et al., 1995).
VEGF-A binding to VEGFR2 triggers receptor dimerisation,
linked to the activation of its tyrosine kinase domain, which
triggers sustained downstream signal transduction integrated with
receptor ubiquitination, trafficking and proteolysis (Bruns et al.,
2009; Horowitz and Seerapu, 2012; Koch and Claesson-Welsh,
2012; Nakayama and Berger, 2013). A key aspect of VEGF-A-
stimulated endothelial cell signal transduction is the elevated
transcription of 100–200 target genes, which regulate a variety of
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cellular responses (Rivera et al., 2011; Schweighofer et al., 2009).
Various studies have shown that VEGF-A isoforms differentially
promote VEGFR2-dependent signal transduction and cellular
outcomes (Kawamura et al., 2008a; Kawamura et al., 2008b;
Zhang et al., 2000). However, the mechanism(s) which link
VEGF-A isoform-specific signal transduction to nuclear gene
transcription and endothelial responses are ill-defined.
To address the individual role of each VEGF-A splice isoform
in regulating vascular function, we evaluated VEGF-A121 and
VEGF-A165 for their ability to regulate signal transduction events
linked to physiological responses. Here, we show that these two
VEGF-A isoforms produce different intracellular signalling
outcomes which impact on a transcriptional ‘switch’ allowing
for isoform-specific regulation of endothelial cell migration.
Thus, VEGF-A isoforms could act as temporal and spatial cues
that program endothelial responses essential for building unique
vascular networks.
RESULTS
VEGF-A isoforms cause differential VEGFR2 activation and
signal transduction
VEGF-A-stimulation promotes VEGFR2 dimerisation and trans-
autophosphorylation of several key tyrosine residues within the
cytoplasmic domain (Koch and Claesson-Welsh, 2012) which
stimulates downstream signal transduction pathways (Fig. 1A).
Recruitment of factors and enzymes that bind activated VEGFR2
stimulates intracellular signalling events which modulate an array
of endothelial cell responses in order to promote angiogenesis and
regulate vascular development (Fig. 1A). Various studies have
shown that VEGF-A isoforms promote differential VEGFR2
activation and downstream signal transduction (Kawamura et al.,
2008b; Pan et al., 2007a). Although, VEGF-A-stimulated
VEGFR2-dependent signalling is well understood, it is still
unclear how VEGF-A isoform-specific signal transduction is
converted into nuclear gene transcription to differentially regulate
endothelial cell responses. In order to further investigate this
phenomenon, we first compared the ability of two VEGF-A
isoforms (VEGF-A165 and VEGF-A121) to regulate signal
transduction events via the VEGFR2/VEGF-A signalling axis.
Primary human umbilical vein endothelial cells (HUVECs) were
titrated with 0.025, 0.25 and 1.25 nM of either VEGF-A165 or
VEGF-A121 for 5 or 15 min prior to processing and immunoblot
analysis of VEGFR2 activation and downstream signalling
pathways (Fig. 1B). Quantification of the relative changes in
phosphorylation status of VEGFR2-pY1175 in response to a dose-
dependent titration of VEGF-A165 (Fig. 1C) or VEGF-A121
(Fig. 1D) revealed that peak activation occurred within 5 min of
ligand treatment. However, VEGF-A121-stimulated VEGFR2-
Y1175 phosphorylation (Fig. 1D) was significantly reduced versus
VEGF-A165 treatment (Fig. 1C) at 0.025 and 0.25 nM. However,
upon stimulation with saturating levels of VEGF-A (1.25 nM), the
peak level of VEGFR2 activation achieved in response to VEGF-
A165 (Fig. 1C) was comparable to that induced by VEGF-A121
(Fig. 1D). Interestingly, at this VEGF-A concentration, activated
VEGFR2 appeared to be dephosphorylated at an increased rate upon
treatment with VEGF-A121 (Fig. 1D) compared to cells treated with
VEGF-A165 (Fig. 1C).
Angiogenesis is a tightly regulated process and many endothelial
cell responses constantly need fine-tuning for homeostasis and
maintenance of vascular physiology (Carmeliet, 2005). VEGF-A
stimulation regulates several endothelial cell responses through the
activation of downstream signalling events including those that
affect endothelial cell permeability (Akt-eNOS pathway), cell
migration (p38 MAPK pathway) and cell proliferation (ERK1/2
pathway). Stimulation with either VEGF-A165 or VEGF-A121
promoted phosphorylation of endothelial nitric oxide synthase
(eNOS), p38 MAPK and ERK1/2 (Fig. 1B) enzymes.
Quantification of eNOS-pS1177 levels revealed that stimulation
with VEGF-A121 (Fig. 1F) resulted in a generally lower level
of activation compared to VEGF-A165 stimulation (Fig. 1E).
However, peak levels of eNOS activation were comparable
between the two isoforms (Fig. 1E,F). Additionally both VEGF-
A isoforms caused a similar increase in p38 MAPK-pT180/pY182
levels at 1.25 nM ligand stimulation, with peak levels detected
after 15 min (Fig. 1G,H). In contrast VEGF-A165 promoted ,2-
fold increase in ERK1/2-T202/Y204 phosphorylation compared to
VEGF-A121 at the same concentration (1.25 nM); peak levels were
still detected 15 min post stimulation (Fig. 1I,J). These findings
suggest that VEGF-A isoforms have the capability to differentially
stimulate multiple signal transduction pathways in endothelial
cells.
VEGF-A isoforms promote differential PLCc1 activation and
corresponding cytosolic calcium ion flux
VEGF-A-stimulated generation of VEGFR2-pY1175 creates a
phosphotyrosine-based epitope that recruits PLCc1 to activated
VEGFR2 at the plasma membrane (Takahashi et al., 2001).
Subsequently, VEGFR2-mediated PLCc1 phosphorylation on
residue Y783 (PLCc1-pY783) leads to enzymatic activation and
hydrolysis of plasma membrane PIP2 to DAG and InsP3 thus
triggering a rise in cytosolic calcium ion flux and altered
endothelial responses (Fig. 2A). To investigate VEGF-A isoform-
specific PLCc1-mediated responses, we monitored PLCc1-
pY783 levels upon titration with VEGF-A165 or VEGF-A121 for
5, 15, 30 or 60 min (Fig. 2B). PLCc1-pY783 levels were clearly
elevated upon addition of VEGF-A165 compared to VEGF-A121
(Fig. 2B) addition to endothelial cells. Quantification revealed
VEGF-A165 stimulated a rapid and transient rise in endothelial
PLCc1-pY783 levels within 5 min (Fig. 2C) but VEGF-A121-
stimulated PLCc1-pY783 peak levels were ,2–3-fold lower
(Fig. 2D).
We then carried out an analysis of cytosolic calcium ion levels in
VEGF-A isoform-stimulated endothelial cells using a cell-
permeable Ca2+-sensitive fluorescent probe (Fura-2 AM). Upon
titration of either VEGF-A165 (Fig. 3A) or VEGF-A121 (Fig. 3B)
we observed different patterns of cytosolic calcium ion flux. The
lowest concentration (0.025 nM) of VEGF-A165 ligand caused a
slow and sustained rise in cytosolic calcium ions (Fig. 3A); this
was not observed upon treatment with 0.025 nM VEGF-A121. A
similar trend was observed at 0.25 nM ligand concentration of
both isoforms (Fig. 3A,B). Interestingly, the highest concentration
(1.25 nM) of ligand elicited similar rises in cytosolic calcium
ions with both VEGF-A165 (Fig. 3A) and VEGF-A121 (Fig. 3B).
Quantification of peak magnitude in ligand-stimulated rise in
cytosolic calcium ion levels revealed that both VEGF-A165 and
VEGF-A121 acted
in a concentration-dependent manner (Fig. 3C). VEGF-A165
stimulation generally promoted an increased level in intracellular
Ca2+ versus treatment with VEGF-A121 (Fig. 3C). However, at
saturating levels of VEGF-A (1.25 nM) the peak magnitude of
cytosolic calcium ion rise was comparable upon stimulation with
either VEGF-A165 or VEGF-A121 (Fig. 3C). In contrast, the time
taken to reach this peak magnitude was ,2-fold longer in VEGF-
A121-stimulated cells in comparison to VEGF-A165 treatment
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Fig. 1. See next page for legend.
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(Fig. 3D). Quantification of the relative curve area at different
VEGF-A concentrations revealed a similar magnitude of response
for VEGF-A165 regardless of concentration; however, VEGF-A121
only induced significant changes in intracellular calcium ion
levels at the maximum concentration of 1.25 nM (Fig. 3E).
These findings suggest that the cytosolic calcium ion flux caused
by the VEGFR2-PLCc1 axis is VEGF-A isoform-dependent
(Fig. 3F).
VEGF-A isoform-dependent nuclear and membrane protein
localisation
Cytosolic calcium ion fluxes can regulate endothelial cell gene
transcription via the calcium-regulated and calmodulin-dependent
activation of the protein phosphatase calcineurin (Domı´nguez-
Rodrı´guez et al., 2012; Zarain-Herzberg et al., 2011). This
enzyme regulates dephosphorylation and subsequent nuclear
translocation of the nuclear factor of activated T-cells (NFAT)
family of transcription factors (Rao et al., 1997; Wu et al., 2007)
(Fig. 4A). VEGF-A can promote nuclear translocation of NFAT
family members such as NFATc2 (Goyal et al., 2012; Zaichuk
et al., 2004). We hypothesised that the differential VEGF-A
isoform-specific regulation of cytosolic calcium ion flux could
modulate activation of endothelial NFATc2. To test this idea,
endothelial cells were stimulated with 0.25 nM of either VEGF-
A165 or VEGF-A121 which elicited the major differences in
cytosolic calcium ion flux, followed by immunoblot analysis of
NFATc2 phosphorylation status (Fig. 4B). This revealed that at
the peak of VEGF-A165-stimulated PLCc1 phosphorylation
(PLCc1-pY783), there was a corresponding increase in NFATc2
activation, reflecting dephosphorylation of this transcription factor
(Fig. 4B). However, at a comparable level of VEGF-A121, we
found a relatively small rise in NFATc2 activation (Fig. 4B).
Quantification of the relative levels of dephosphorylated (active)
vs. phosphorylated (inactive) NFATc2 revealed that both VEGF-A
isoforms simulated rapid and transient dephosphorylation, with
peak dephospho-NFATc2 levels occurring after,5 min (Fig. 4C).
However, VEGF-A165 stimulation promoted ,22-fold increase in
dephospho-NFATc2, whereas VEGF-A121 stimulation caused a
significantly lower rise (,2-fold) in dephospho-NFATc2 levels
(Fig. 4C).
Nuclear translocation of dephosphorylated NFATc2 is required
for the modulation of endothelial gene expression (Wu et al.,
2007). To test the idea that VEGF-A isoform-specific NFATc2
dephosphorylation regulates its nuclear translocation we evaluated
the intracellular distribution of NFATc2 in response to VEGF-A
isoform stimulation (Fig. 5). Endothelial cells were stimulated
with either VEGF-A165 or VEGF-A121 (0.25 nM) for 0, 5, 15 or
30 min before fixation and processing for immunofluorescence
analysis (Fig. 5A). Addition of VEGF-A165 caused rapid and
sustained NFATc2 accumulation within the nucleus within a
30 min period (Fig. 5A). However, VEGF-A121 stimulation
resulted in relatively low nuclear accumulation within a 30 min
period (Fig. 5A). Quantification of NFATc2 nuclear co-
distribution in a ligand- and time-dependent manner revealed
,18-fold (VEGF-A165) or ,3-fold (VEGF-A121) increase in peak
Fig. 1. VEGF-A isoform-specific stimulated endothelial cell signalling.
(A) Schematic depicting VEGF-A stimulated VEGFR2 phosphorylation,
activation of downstream signalling pathways linking to cellular responses.
Abbreviations: p38, p38 mitogen-activated protein kinase; HSP27, heat-
shock protein of 27 kDa; Akt, Protein kinase B; eNOS, endothelial nitric oxide
synthase; NO, nitric oxide; MEK1, mitogen-activated protein kinase 1; ERK1/
2, p42/44 mitogen-activated protein kinase. (B) Endothelial cells subjected to
different VEGF-A165 or VEGF-A121 concentrations (0, 0.025, 0.25 or
1.25 nM) for 5 or 15 min were lysed and processed for immunoblot analysis
using phospho-specific antibodies against p-VEGFR2, p-eNOS, p-p38 and
p-ERK1/2. (C–J) Quantification of VEGF-A isoform-specific signal
transduction events. Quantification of (C,D) VEGFR2-pY1175, (E,F) eNOS-
pS1177, (G,H) p38 MAPK-pT180/pY182 or (I,J) ERK1/2-pT202/Y204 upon
(C,E,G,I) VEGF-A165 or (D,F,H,J) VEGF-A121 stimulation. Error bars indicate
6SEM (n§3). p,0.05 (*), p,0.01 (**), p,0.001 (***), p,0.0001 (****).
Fig. 2. VEGF-A isoform-specific
stimulated PLCc1 activation.
(A) Schematic depicting VEGF-A-
stimulated VEGFR2-pY1175 recruitment of
PLCc1, subsequent phosphorylation and
activation. (B) Endothelial cells subjected to
different VEGF-A165 or VEGF-A121
concentrations (0, 0.025, 0.25 or 1.25 nM)
for 5, 15, 30 or 60 min were lysed and
probed for phospho-PLCc1.
(C,D) Quantification of PLCc1-pY783 levels
upon (C) VEGF-A165 or (D) VEGF-A121
stimulation. Error bars indicate 6SEM
(n§3). p,0.05 (*), p,0.001 (***),
p,0.0001 (****).
RESEARCH ARTICLE Biology Open (2015) 4, 731–742 doi:10.1242/bio.201410884
734
B
io
lo
g
y
O
p
e
n
nuclear NFATc2 levels (Fig. 5B). Interestingly, biochemical
analysis of NFATc2 phosphorylation status after VEGF-A165
stimulation for 30 min showed that phosphorylated activated
NFATc2 levels had returned to baseline (Fig. 4B) but the
morphological analysis revealed a major pool of NFATc2 still
present within the nucleus at the 30 min time point (Fig. 5A,B).
Thus initial dephosphorylation of NFATc2 is sufficient to promote
rapid cytosol-to-nuclear translocation but nuclear retention occurs
via a different mechanism.
Cytosolic calcium ion fluxes have also been linked to promoting
trafficking of another endothelial receptor tyrosine kinase
(VEGFR1) from the Golgi apparatus to the plasma membrane
(Bruns et al., 2009; Mittar et al., 2009). Due to the different
abilities of the two VEGF-A isoforms in promoting the release of
intracellular calcium ion stores (Fig. 3A–E), we hypothesised
about effects on VEGFR1 translocation to the plasma membrane.
To test this idea, we stimulated endothelial cells with either VEGF-
A165 or VEGF-A121 for 0, 15, 30 or 60 min prior to assessing
plasma membrane VEGFR1 using cell surface biotinylation
(supplementary material Fig. S1A). Immunoblot analysis of
mature and soluble VEGFR1 expression revealed that in
non-stimulated endothelial cells, both forms of VEGFR1 are
predominately located within internal, biotin probe-inaccessible
compartments and not at the plasma membrane (supplementary
material Fig. S1A). However, upon stimulation with VEGF-A165
there was a significant increase (,2.5-fold) in both mature
(supplementary material Fig. S1B) and soluble (supplementary
material Fig. S1C) VEGFR1 (sVEGFR1/sFlt1) at the cell
surface. Contrastingly, VEGF-A121 treatment failed to promote a
significant increase in cell surface levels of either mature or
sVEGFR1 (supplementary material Fig. S1A,B).
VEGF-A-stimulated endothelial cell migration is
NFATc2-dependent
VEGF-A-stimulated signal transduction regulates a diverse
number of long-term endothelial cells responses, such as cell
migration and tubulogenesis (Chung and Ferrara, 2011; Koch
et al., 2011). VEGF-A isoforms have been shown to differentially
regulate endothelial cell responses (Kawamura et al., 2008b).
However, the transcription factors involved in regulating these
isoform-specific cellular responses are not well defined. To
determine whether NFATc2 is required for the diverse array of
Fig. 3. VEGF-A isoform-specific release
of intracellular Ca2+. (A,B) Real-time
monitoring of cytosolic Ca2+ flux with
(A) VEGF-A165 or (B) VEGF-A121 titration;
graphs show a representative plot of
multiple experiments. Error bars indicate
6SEM (n51, N54). (C–E) Quantification of
(C) peak magnitude, (D) time taken to reach
peak magnitude or (E) the total curve area
upon stimulation with VEGF-A165 and
VEGF-A121. Error bars indicate 6SEM
(n53). (F) Schematic depicting VEGF-A-
stimulated second messenger targeting of
InsP3 receptors (InsP3R) and subsequent
cytosolic calcium ion rise. PtdIns(4,5)P2
hydrolysis to generate diacylglycerol (DAG)
and Ins(1,4,5)P3 is depicted. p,0.05 (*),
p,0.01 (**), p,0.0001 (****).
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VEGF-A-stimulated endothelial cell responses, we used reverse
genetics combined with ligand-stimulated cellular assays (Fig. 6).
We used siRNA duplexes to knockdown NFATc2 levels in
endothelial cells and compared to scrambled siRNA duplex-
treated or non-transfected controls (Fig. 6). Treatment with
NFATc2-specific siRNA duplexes caused ,90% knockdown in
endothelial NFATc2 levels (supplementary material Fig. S2A,B),
but did not affect expression of other endothelial proteins such as
VEGFR2, VEGFR1 and ERK1/2 (supplementary material Fig.
S2A). To determine the effect of NFATc2 knockdown on
endothelial cell migration and tubulogenesis, NFATc2-depleted
or control endothelial cells were stimulated with 0.25 nM VEGF-
A165 or VEGF-A121, before fixation, staining and processing
for light microscopy (Fig. 6A). As previously reported
elsewhere, VEGF-A165 has a ,2–3-fold higher efficacy for
promoting endothelial cell migration (Fig. 6B,C). Interestingly,
quantification revealed that depletion of NFATc2 caused ,2–3-
fold increase in basal cell migration in non-stimulated endothelial
cells (Fig. 6B), during comparison of all values to non-transfected
non-stimulated endothelial cells. In such an analysis, there
appears to be relatively little change in VEGF-A isoform-
stimulated cell migration upon scrambled siRNA treatment or
NFATc2 knockdown (Fig. 6B). However, when each experiment
was compared to their own non-stimulated control which had
been also subjected to scrambled or NFATc2 siRNA, a different
pattern emerged (Fig. 6C). There was now a substantial 3–4-fold
decrease in both VEGF-A165 and VEGF-A121-stimulated
endothelial cell migration in NFATc2 depleted endothelial cells
(Fig. 6C).
An important aspect of the VEGF-A-stimulated endothelial
cell response is the capacity to build hollow tubes (tubulogenesis)
which can be monitored using an organotypic assay. Using this
technique, we asked whether NFATc2 was required for VEGF-A-
stimulated tubulogenesis (Fig. 6D). As previously reported
elsewhere, VEGF-A165 has a ,2–3-fold higher efficacy for
promoting endothelial cell tubulogenesis, in comparison to
VEGF-A121 (Fig. 6E,F). Intriguingly, NFATc2 did not
significantly affect VEGF-A stimulated endothelial cell
tubulogenesis (Fig. 6D). Quantification revealed that NFATc2
knockdown did not affect endothelial tubule length (Fig. 6E) nor
branch point complexity (Fig. 6F).
Fig. 4. VEGF-A isoform-specific Ca2+
flux promotes differential NFATc2
activation. (A) Schematic depicting VEGF-
A-stimulated cytosolic calcium ion rise and
effects on NFATc2 dephosphorylation and
nuclear translocation. (B) Endothelial cells
subjected to stimulation with 0.25 nM
VEGF-A165 or VEGF-A121 for 5, 15, 30 and
60 min were lysed and process for
immunoblot analysis to detect phospho-
(inactive) and dephospho- (active) NFATc2
species. (C) Quantification of relative active
versus inactive NFATc2 levels upon
stimulation with VEGF-A165 and VEGF-
A121. Error bars indicate 6SEM (n53).
p,0.05 (*), p,0.001 (***).
Fig. 5. VEGF-A isoforms promote differential NFATc2 nuclear
translocation. (A) Endothelial cells stimulated with 0.25 nM VEGF-A165 or
VEGF-A121 for 5, 15 and 30 min were fixed and processed for
immunofluorescence microscopy using rabbit anti-NFATc2 (green); nuclei
stained using DAPI (blue). Scale bar, 1000 mm. (B) Quantification of NFATc2
nuclear co-distribution at 0, 5, 15 and 30 min after stimulation with VEGF-
A165 or VEGF-A121. Error bars indicate 6SEM (n53). p,0.0001 (****).
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DISCUSSION
In this study, we show that different VEGF-A isoforms have
differing capabilities to modulate endothelial cell migration by
regulating the activation and nuclear localisation of a key
transcription factor (Fig. 7). In our proposed model, two
VEGF-A isoforms with similar binding affinities differentially
program VEGFR2 activation and downstream signal transduction
which controls a transcriptional ‘switch’ that regulates
endothelial cell migration. This ‘switch’ comprises the calcium-
dependent activation of the calmodulin-calcineurin pathway
which targets endothelial NFATc2, a key transcription factor
(Fig. 7).
A key feature of endothelial cell migration is the VEGF-A
isoform-specific programming of signal transduction and this
cellular response. VEGF-A165 significantly promoted increased
VEGFR2 phosphorylation at residue Y1175 in comparison to
VEGF-A121. The generation of this unique pY1175 binding site
enables recruitment of PLCc1 via its SH2 domains and
subsequent phosphorylation on residue Y783. VEGF-A isoform-
specific stimulation of PLCc1-pY783 levels correlated with
increased cytosolic calcium ion flux (Fig. 7). Calmodulin is a key
target of elevated cytosolic calcium ion levels and upon calcium
ion binding to one of its four EF hands, undergoes a
conformational change that promotes interaction with new
cellular targets, including the protein phosphatase calcineurin
(Berchtold and Villalobo, 2014). Calmodulin binding to
calcineurin promotes enzymatic activation; one such target is
NFATc2, resulting in its subsequent rapid dephosphorylation and
nuclear targeting (Luo et al., 1996; Okamura et al., 2000). Both
VEGF-A165 and VEGF-A121 stimulation promotes cytosolic
calcium ion flux, NFATc2 dephosphorylation and nuclear
translocation but to widely differing extents (Fig. 7). Depletion
of endothelial NFATc2 levels significantly reduced VEGF-A-
stimulated endothelial cell migration suggesting that this factor
plays a role in controlling gene expression linked to cell
migration processes e.g. focal adhesion, stress fibre formation
Fig. 6. NFATc2 regulates VEGF-A isoform-specific
endothelial cell migration but not tubulogenesis.
(A–F) Control, scrambled or NFATc2-specific siRNA
duplex-treated endothelial cells were seeded into assays
to assess endothelial cell (A–C) migration or
(D–F) tubulogenesis. (A) Endothelial cells seeded into
Transwell filters were stimulated with 0.25 nM VEGF-A165
or VEGF-A121 for 24 h before being fixed and stained
with 20% (v/v) crystal violet. Scale bar, 1000 mm.
(B,C) Quantification of endothelial cell migration
compared to (B) non-transfected or (C) individual
controls. Error bars indicate 6SEM (n§3).
(D) Endothelial cells subjected to different siRNA
treatments were co-cultured on a bed of primary human
fibroblast for 7 days and stimulated with 0.25 nM VEGF-
A165 or VEGF-A121. Co-cultures were fixed and
endothelial tubules were stained and visualised using an
anti-PECAM1 antibody followed by fluorescent
secondary antibody. Scale bar, 1000 mm.
(E,F) Quantification of endothelial cell tubulogenesis
including total (E) tubule length or (F) number of branch
points. Error bars indicate 6SEM (n§3). p,0.05 (*),
p,0.01 (**), NS5non-specific.
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and actin polymerisation (Fig. 7). Although, our results show that
VEGF-A isoforms promote NFATc2 translocation into the
nucleus, a lacking area of investigation is to determine if
VEGF-A-stimulated NFATc2 dephosphorylation and nuclear
translocation leads to the transcription of well-known NFATc2
regulated genes. However, it is highly likely that this is the case,
due to the effect that depletion of NFATc2 has on VEGF-A-
stimulated endothelial cell migration.
Various transcription factors such as ATF-2, NFAT, STAT3,
forkhead-like transcription factors, FoxO- and ETS-related
transcription factors are implicated in VEGF-A-dependent gene
expression and physiological responses (Abid et al., 2006;
Armesilla et al., 1999; Bartoli et al., 2003; Dejana et al., 2007;
Fearnley et al., 2014a; Liu et al., 2003; Potente et al., 2005).
However, the role of NFATc2 in VEGF-A stimulated
angiogenesis is poorly defined. Previous studies have suggested
a role for the transcriptional activity of endothelial NFATc2 in
mediating VEGF-A-stimulated retinal angiogenesis (Zaichuk
et al., 2004) and endothelial cell tubulogenesis (Goyal et al.,
2012). Thus, our study now identifies a novel role for NFATc2 in
Fig. 7. Mechanism for VEGF-A isoform-
specific regulation of endothelial cell
migration. Schematic depicting VEGF-A
isoform-specific regulation of NFATc2
activation and regulation of endothelial cell
migration. Numbered steps denote: (1)
VEGF-A isoforms promote differential
recruitment and activation of PLCc1
through interaction with VEGFR2; (2) due to
increased PLCc1 activation, VEGF-A165
promotes an increased rise in intracellular
Ca2+, versus VEGF-A121; (3) Increased
VEGF-A165 stimulated intracellular Ca
2+ flux
results in increased NFATc2
dephosphorylation, versus VEGF-A121; (4)
dephosphorylated NFATc2 translocates into
the nucleus where it regulates endothelial
gene transcription; (5) VEGF-A-stimulated
NFATc2 regulated gene expression
promotes endothelial cell migration.
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the regulation of VEGF-A isoform-specific endothelial cell
migration (Fig. 7). However, in contrast to work elsewhere
(Bala et al., 2012), we did not find that NFATc2 was essential for
VEGF-A-stimulated endothelial cell tubulogenesis. One possible
explanation lies within the choice of assay used to monitor
endothelial cell tubulogenesis. In our study we used a 7 day
human fibroblast-endothelial cell co-culture assay to monitor the
formation of PECAM-1 positive endothelial tubules, where Bala
and colleagues performed a Matrigel co-culture assay (Bala et al.,
2012); one drawback of this assay is that does not give an
accurate index of endothelial cell tube formation (Donovan et al.,
2001). Another reason could be the method used to look at
NFATc2 involvement in endothelial cell function. In our study
we used RNAi to directly deplete 90% of endothelial NFATc2.
Bala and colleagues were studying the effects of a Kaposi’s
Sarcoma Herpesvirus protein (K15) on stimulating NFATc2-
dependent RCAN1 expression (Bala et al., 2012). Therefore, it is
possible that VEGF-A and K15-stimulated NFATc2 activation
play different roles in determining endothelial cell fate. The fact
that NFATc2 does not appear to be required for endothelial tube
formation but is required for endothelial cell motility is surprising,
as the latter is required for the former. This is a serious limitation to
our current study and further work is required, the use of more
robust 3-D angiogenesis assays such as the fibrin bead and ‘ex vivo’
mouse aortic ring assay would help strengthen the conclusions
made here. Additionally, the monitoring of endothelial cell motility
in real-time would further strengthen the role of NFATc2 in
regulating VEGF-A isoform-specific cell migration. Likewise,
analysis of other VEGF-A-stimulated endothelial responses (e.g.
cell proliferation and permeability) for NFATc2 dependency
would prove informative.
Interestingly, we found that basal NFATc2 activity inhibits the
rate of cell migration in non-stimulated endothelial cells. One
possible explanation could lie within the fact that NFATc2
naturally functions in an auto-inhibitory manner by promoting the
expression of regulator of calcineurin 1 (RCAN1). RCAN1 forms
a complex with calcineurin to directly inhibit its phosphatase
activity, thus preventing calcineurin-dependent NFATc2
dephosphorylation and nuclear translocation (Holmes et al.,
2010; Li et al., 2011). However, calcineurin also activates
receptor for activated protein kinase C1 (RACK1), which has
been implicated in regulating cell migration through binding to an
array of signalling proteins. Endothelial cells constitutively
express RCAN1 at a basal level (Holmes et al., 2010; Me´ndez-
Barbero et al., 2013). Thus, depleting NFATc2 could reduce basal
levels of RCAN1, subsequently leading to increased endothelial
cell migration through attenuated calcineurin-stimulated RACK1
signalling. Calcineurin inhibitors have also been shown to inhibit
cell migration (Espinosa et al., 2009; Siamakpour-Reihani et al.,
2011), thus strengthening this proposed mechanism. RCAN1 is
one of the most highly expressed gene products in response to
VEGF-A-stimulation (Rivera et al., 2011; Schweighofer et al.,
2009). Therefore, it is likely to have an essential role in regulating
VEGF-A mediated endothelial responses. Various studies have
shown that RCAN1 is essential for cellular migration (Espinosa
et al., 2009; Holmes et al., 2010; Iizuka et al., 2004; Ryeom et al.,
2008). Hence, VEGF-A isoform-specific elevation in RCAN1
expression could account for the reduction in VEGF-A-stimulated
endothelial cell migration in NFATc2-depleted endothelial
cells. Additionally, VEGF-A isoform-specific NFATc2-
dependent upregulation of RCAN1 could also account for the
differences in their abilities to stimulate endothelial cell migration.
One question left unanswered is what is the mechanism(s)
behind how these two VEGF-A isoforms with similar binding
affinities, promote such diverse activation of VEGFR2 and
downstream signalling enzymes. One possible answer is through
the differential binding and recruitment of co-receptors (e.g.
NRP-1, NRP-2 and HSPG). Neuropilin 1 (NRP-1) is a VEGF-A
isoform-specific co-receptor (Zachary et al., 2009). VEGF-A165
binds to the co-receptor neuropilin 1 (NRP1) to form a VEGFR2/
NRP1/VEGF-A165 signalling complex (Fantin et al., 2013;
Herzog et al., 2011; Raimondi and Ruhrberg, 2013; Zachary
et al., 2009). Formation of this trimeric complex has been shown
to increase VEGF-A165-stimulated VEGFR2 activation,
downstream signalling and endothelial responses (Allain et al.,
2012; Kawamura et al., 2008a; Koch, 2012). However, VEGF-
A121 binding simultaneously to VEGFR2 and NRP1 has been
contradicted (Pan et al., 2007b). Thus VEGF-A isoform-specific
recruitment of NRP-1 could account for the differences in
signalling between the 2 isoforms.
VEGF-A-stimulated NFATc2-dependent gene expression is
said to occur in co-operation with the transcription factor early
growth response 1 (EGR-1) (Schweighofer et al., 2007). VEGF-A
stimulates EGR-1 gene expression through the MEK1-ERK1/2
pathway (Schweighofer et al., 2007). As we show that VEGF-
A165 and VEGF-A121 have differential effects on ERK1/2
activation, one future study would be to investigate if these 2
isoforms differentially activated EGR-1 as a means of
programing isoform-specific endothelial cell responses.
VEGFR1 binds VEGF-A with a much higher affinity than
VEGFR2 (de Vries et al., 1992), yet its involvement in VEGF-A
stimulated angiogenesis is not well understood. One view is that
both membrane-bound and sVEGFR1 proteins act primarily as
VEGF-A ‘traps’, thus limiting ligand availability for the major
pro-angiogenic receptor, VEGFR2 (Rahimi, 2006). However,
VEGF-A-regulated VEGFR1-linked signal transduction has
been implicated in certain aspects of endothelial cell
physiology (Koch and Claesson-Welsh, 2012). In non-
stimulated endothelial cells, VEGFR1 is primarily inaccessible
to VEGF-A, as it is located within an internal compartment
resembling the Golgi apparatus (Mittar et al., 2009). VEGF-A165
stimulation promotes VEGFR1 translocation to the cell surface
via a cytosolic calcium ion-dependent mechanism where it can
bind exogenous VEGF-A. In this study, VEGF-A165 promoted
significant trafficking of VEGFR1 to the plasma membrane
whereas VEGF-A121 was largely ineffective in this context;
again this could be explained by signal transduction effects on
cytosolic calcium ion levels. The role of VEGF-A isoforms in
differential VEGFR1 trafficking could further modulate the
endothelial cell response to this ligand, as not only would this
affect VEGF-A bioavailability for VEGFR2, but regulate
VEGFR1-specific signal transduction in response to VEGF-A,
VEGF-B and PlGF isoforms and thus regulate vascular
physiology.
The physiological process of angiogenesis can be destabilised
in a wide variety of major disease states ranging from
atherosclerosis, rheumatoid arthritis, pathogenic infection to
cancer. Current anti-angiogenic therapies which try to restrict
pathological angiogenesis, by sequestering endogenous VEGF-A
or via inhibiting RTK activity, are not as successful as first hoped.
This is partially due to tumour cell-acquired resistance through
the activation of alternative angiogenic pathways, in addition to
other assorted mechanisms (Vasudev and Reynolds, 2014).
Therefore, further investigation into the mechanisms which
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regulate angiogenesis is required. This will hopefully lead to
improved patient outcomes in various disease states, through the
design of better therapeutics. Our study now provides a novel
mechanism to explain how different VEGF-A isoforms act on a
common receptor tyrosine kinase (VEGFR2) to differentially
determine a specific endothelial cell outcome (i.e. cell migration;
Fig. 7). Additionally, this work shines new light on the
physiological importance of NFATc2 in regulating VEGF-A-
stimulated endothelial cell migration. A substantial future
challenge will be to determine the biological significance of
each VEGF-A isoform in healthy and diseased states.
MATERIALS AND METHODS
Antibodies and growth factors
Antibodies: goat-anti-VEGFR2 (R&D Systems, Minneapolis, MN,
USA), goat-anti-VEGFR1 (R&D Systems), rabbit-anti-ERK1/2, mouse-
anti-phospho-ERK1/2 (Thr202/Tyr204), rabbit-anti-p38, rabbit-anti-
phospho-p38 (Thr180/Tyr182), rabbit-anti-phospho-VEGFR2 (Tyr1175),
rabbit-anti-eNOS, rabbit-anti-phospho-eNOS(Ser1177), rabbit-anti-
phospho-PLCc1(Tyr783), rabbit-anti-NFATc2 (Cell Signaling
Technology, Danvers, MA, USA), mouse anti-PECAM-1 (CD31),
rabbit-anti-PLCc1 (Santa Cruz Biotechnology, Dallas, TX, USA) and
mouse-anti-a-tubulin (Sigma-Aldrich, Poole, UK). Reagents: Endothelial
cell growth medium (ECGM) was from PromoCell (Heidelberg,
Germany). Scrambled and NFATc2 siRNA duplexes were purchased as
siGENOME SMARTpools from Dharmacon (Thermo Scientific,
Lafayette, USA). Recombinant human VEGF-A165 was from Genentech
Inc. (San Francisco, CA, USA) and VEGF-A121 was from Promocell.
Cell culture
Human umbilical vein endothelial cells (HUVECs) were isolated as
previously described (Howell et al., 2004). Human umbilical cords were
obtained after written informed consent from volunteers. Tissue retrieval
was governed by local ethics approval from the Leeds Hospitals NHS
Trust. HUVECs were only used between passage P1 and P5. Cells were
seeded into 6-well plates and cultured (for at least 24 h) in ECGM until
,80% confluent, washed three times with PBS and then starved in
MCDB131 + 0.2% (w/v) BSA for 2–3 h. HUVECs were then stimulated
with 0, 0.025, 0.25 or 1.25 nM of VEGF-A165 or VEGF-A121 prior to
processing.
Cell lysis and processing for immunoblotting
Cells were washed with ice-cold PBS, prior to lysis in 2% (w/v) SDS in
TBS containing 1 mM PMSF and protease inhibitor cocktail (Sigma-
Aldrich) and stored at 220 C˚. Protein concentration was then determined
using the bicinchoninic acid (BCA) assay (ThermoFisher). Protein lysate
was diluted in an equal amount of 26SDS-sample buffer and subjected
to SDS-PAGE prior to analysis via immunoblotting.
Cytosolic calcium ion flux assay
2.56104 HUVECs were seeded per well of a 96-well plate and cultured for
48 h until 100% confluent. Cells were washed twice with 100 ml SBS
buffer (130 mM NaCl, 5 mM KCl, 1.2 mM MgCl2, 8 mM glucose,
10 mM HEPES, 1.5 mM CaCl2, pH 7.4) and loaded with 50 ml Fura-2
AM/SBS (2 mM Fura-2-AM, 0.01% Pluronic F-127; Life Technologies,
Paisley, UK) for 60 min at 37 C˚. Cells were then washed twice with 100 ml
SBS and left at room temperature for 30 min to allow complete de-
esterification of Fura-2-AM. Desired concentration of VEGF-A isoform
was made up as a 56stock in a compound plate. Cytosolic calcium ion rise
was monitored by measuring the ratio of 510 nm emission achieved from
excitation at 340 nm vs. 380 nm using a FlexStation Benchtop Microplate
Reader (Molecular Devices, Sunnyvale, USA). VEGF-A was added
automatically after 32 s and Ca2+ levels were measured every 5 s for a total
of 900 s. Change in cytosolic Ca2+ fluctuations as a function of time were
plotted and quantified by calculating the peak magnitude, time take to
reach peak magnitude and the area under the curve using OriginPro 8.6
(OriginLab, USA).
Immunofluorescence analysis of NFATc2 localisation
HUVECs cultured in 96-well plates were serum starved for 3 h before
being stimulated with 0.25 nM VEGF-A165 or VEGF-A121. Media was
aspirated and cells incubated with fixative (Sigma-Aldrich) for 5 min at
37 C˚ before permeabilisation in 0.2% (v/v) Triton X-100 in PBS. Cells
were blocked in 5% (w/v) BSA prior to incubation with rabbit-anti-
NFATc2 in 1% (w/v) BSA overnight at 4 C˚. Primary antibody was
aspirated and cells washed, before incubation with 4 mg/ml donkey anti-
rabbit Alexaflour488-conjugated secondary antibody (Invitrogen,
Amsterdam, Netherlands), 2 mg/ml 4,6-diamidino-2-phenylidole (DAPI)
in 1% (w/v) BSA in PBS and incubated for 2–3 h at room temperature.
Images were acquired using an EVOS-fl inverted digital microscope
(Life Technologies). 3 random fields were captured per sample. Relative
nuclear co-localisation was quantified using Image J as previously
described elsewhere (Bruns et al., 2010; Jopling et al., 2011).
Lipid-based transfection of siRNA duplexes
HUVECs were reversed transfected using siRNA duplexes and
Lipofectamine RNAiMAX (Life Technologies). Per well of a 6-well
plate, 15 ml of 2 mM siRNA duplex was added to 481 ml of serum/
antibiotic-free OptiMEM (Life Technologies) and allowed to react at
room temperature for 5 min. 4 ml of Lipofectamine was then added to
the siRNA duplex/OptiMEM mixture, inverted briefly and incubated at
room temperature for 20 min. 2.56105 HUVECs in 1 ml of OptiMEM
were seeded, followed by immediate dropwise addition of the siRNA/
lipofectamine mixture. Cells were incubated at room temperature
for 30 min before being returned to the incubator. After 6 h total
incubation, transfection media was aspirated and replaced with ECGM.
Cells were allowed to recover for 72 h prior to analysis of endothelial
responses.
Cell migration assay
36104 HUVECs were seeded in MCDB131 media containing 0.2% (w/v)
BSA onto a 8 mm pore size Transwell filter [pre-coated with 0.1% (v/v)
pig skin gelatin (PSG)] inserted into a 24-well plate (BD Biosciences,
Oxford, UK). MCDB131+0.2% (w/v) BSA containing60.25 nM VEGF-
A isoform was added to the lower chambers to stimulate cell migration.
Cells were allowed to migrate for 24 h prior to fixation and staining with
0.2% (w/v) crystal violet in 20% (v/v) methanol. Prior to fixation
endothelial cells were visualised by phase contrast microscopy to ensure
the number of adherent cells were comparable between Transwells. This
ensures that differences seen in the number of migrating cells, was indeed
caused by a defect in cell motility and not due to defective cell adhesion.
Non-migrated cells were removed from the upper chamber with a moist
cotton bud. Transwell filters were imaged and the number of migratory
cells counted as previously described (Fearnley et al., 2014b).
Tubulogenesis assay
Primary human foreskin fibroblasts (Promocell) were cultured in 48-well
plates until confluent in complete DMEM containing 10% FCS, 1% non-
essential amino acids and 1% sodium pyruvate (Life Technologies). 6500
HUVECs were then seeded onto the fibroblast monolayer in a 1:1
mixture of complete DMEM containing 10% (v/v) FCS, non-essential
amino acids, sodium pyruvate and ECGM and left to adhere for 24 h.
Culture media was then removed and replaced with fresh ECGM
6VEGF-A as desired; media was replaced every 2–3 days for 7 days.
Co-cultures were then fixed and blocked prior to overnight incubation
with 1 mg/ml mouse anti-human PECAM-1 (CD31; Santa Cruz
Biotechnology) at room temperature. Co-cultures were washed three
times with PBS before incubation with 1 mg/ml donkey anti-mouse
Alexaflour594-conjugate (Invitrogen) for 2–3 h at room temperature.
Endothelial tubules were then visualised by immunofluorescence
microscopy using an EVOS-fl inverted digital microscope (Life
Technologies). Three random fields were imaged per well. Both the
number of branch points and the total tubule length was then quantified
from each photographic field using the open source software AngioQuant
(www.cs.tut.fi/sgn/csb/angioquant) and values averaged. A more detailed
methodology is available elsewhere (Fearnley et al., 2014b).
RESEARCH ARTICLE Biology Open (2015) 4, 731–742 doi:10.1242/bio.201410884
740
B
io
lo
g
y
O
p
e
n
Statistical analysis
Statistical analysis was performed using one-way analysis of variance
(ANOVA) followed by Tukey’s post-hoc test or two-way ANOVA
followed by Bonferroni multiple comparison test using GraphPad Prism
software (La Jolla, CA, USA). Significant differences between control
and test groups are denoted with p values less than 0.05 (*), 0.01 (**),
0.001 (***) and 0.0001 (****) indicated. Graphical error bars denote
6SEM (standard error of mean).
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